i
References
Aguirre N, Beal MF, Matson WR, et al. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radic Res. 2005;39:383-88
Alexianu ME, Kozovska M, Appel SH. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001;57:1282–89
Anholt RR, Pedersen PL, De Souza EB, et al. The peripheral-type benzodiazepine receptor. Localization to the mitochondrial outer membrane. J Biol Chem. 1986;261:576-83
Antkiewicz-Michaluk L, Guidotti A, Krueger KE. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. Mol Pharmacol. 1988;34:272-8
Azevedo FA, Carvalho LR, Grinberg LT, et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol. 2009;513:532-41
Barbeito LH, P ehar M, Cassina P, et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev. 2004;47:263–74
Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron. 2008;60:430–40
Bassotti G, Villanacci V, Antonelli E et al. Enteric glial cells: new players in gastrointestinal motility? Laboratory Investigation. 2007;87:628–32
Baumann N and Pham-Dinh, D. Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System. Physiological Reviews. 2001;18:871–927
Beal MF, Ferrante RJ, Browne SE, et al. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol. 1997;42:644-54
ii
Beckett RP, Davidson AH, Drummond AH, et al. Recent advances in matrix metalloproteinase inhibitor research. Drug Discov Today. 1996;1:16-26
Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007:26:1–13
Boill´ee S, Yamanaka K, Lobsiger CS et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389–92
Boroujerdi A, Kim HK, Lyu YS, et al. Injury discharges regulate calcium channel alpha-2-delta-1 subunit upregulation in the dorsal horn that contributes to initiation of neuropathic pain. Pain. 2008;139:358-66
Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022–30
Braestrup C. Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H) diazepam binding. Proc Natl Acad Sci USA.
1977;74:3805-09
Briard E, Zoghbi S, Imaizumi M et al. Synthesis and Evaluation in Monkey of Two Sensitive 11C-Labeled Aryloxyanilide Ligands for Imaging Brain Peripheral Benzodiazepine Receptors In Vivo. J Med Chem. 2008;51:17–30
Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti- tumour activity. Ann Oncol. 1995;6:967-74
Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annual Review of Neuroscience. 2004;27:723–49
Campbell K and Götz M. Radial glia: multi-purpose cells for vertebrate brain development. Trends Neurosci. 2002;25:235–8
iii
Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007;42:113-85
Cerami E, Demir E, Schultz N, et al. Automated network analysis identifies core pathways in glioblastoma. PLoS One. 2010;5:e8918
Charles NA, Holland EC, Gilbertson R, et al. The Brain Tumor Microenvironment. Glia. 2011;59:1169–80
Chelli B, Lena A, Vanacore R, et al. Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol. 2004;68:125-34
Chelli B, Rossi L, Da Pozzo L, et al. PIGA (N,N-Di-n-butyl-5-chloro-2-(4- chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells. Chembiochem. 2005;6:1082-8
Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003;3:102-9
Chen MK and Guilarte RT. Translocator Protein 18 kDa (TSPO):Molecular Sensor of Brain Injury and Repair. Pharmacol Ther. 2008;118:1–17
Cheng Y and Prusoff WH. Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which Causes 50 per cent Inhibition (I50) of an Enzymatic Reaction. Biochem Pharmacol. 1973;22:3099–108
Clement AM, Nguyen MD, Roberts EA et al. Wild-type non-neuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science.
2003;302(5642):113–17
Conrad CA, Milosavljevic VP, Yung WK, et al. Advances in chemotherapy for brain tumors. Neurol Clin. 1995;13:795–812
iv
Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387-92
Culty M, Li H, Boujrad N, et al. In vitro studies on the role of the peripheral- type benzodiazepine receptor in steroidogenesis. J Steroid Biochem Mol Biol.
1999;69:123-30
Da Settimo F, Simorini F, Taliani S, et al. Anxiolytic-Like Effects of N,N- Dialkyl-2-phenylindol-3-ylglyoxylamides by Modulation of Translocator Protein Promoting Neurosteroid Biosynthesis. J Med Chem. 2008;51:5798-806
De Keyser J, Mostert JP, Koch MW. Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci. 2008;267:3–16
Daly CJ, McGrath JC. Fluorescent Ligands, Antibodies, and Proteins for the Study of Receptors Pharmacol Ther. 2003;100:101–8
Delavoie F, Li H, Hardwick M, et al. Reactive oxygen species induce in vivo and in vitro peripheral-type benzodiazepine receptor polymerization: changes in drug ligand and cholesterol binding. Biochemistry. 2003;42:4506-19
Dewil M, Lambrechts D, Sciot R et al. Vascular endothelial growth factor counteracts the loss of phospho-Akt preceding motor neurone degeneration in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology. 2007;33:499–
509
Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem. 2007;102:522-38
Di Giorgio FP, Boulting GL, Bobrowicz S, et al. Human embryonic stem cell- derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS causing mutation. Cell Stem Cell. 2008;3:637–48
v
Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci.
2007;10:608–14
Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo, Proc Natl Acad Sci U S A. 1995;92:9363-7
Dollè F, Luus C, Reynolds A et al. Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography. Curr Med Chem.
2009;16:2899–923
Doorduin J, de Vries EF, Dierckx RA et al., PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders. Curr Pharm Des. 2008;14:3297–15
Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain.
Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 2000;267:4912–6
Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis.
Neurodegenerative Diseases. 2004;1:88–100
Ferraiuolo L, Kirby J, Grierson AJ, et al. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 2011:616-30
Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem.
1997;69:2064-74
Ferrante RJ, Shinobu LA, Schulz JB, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation.
Ann Neurology. 1997;42:326-34
vi
Ferrero P, Costa E, Conti-Tronconi B, et al. A diazepam binding inhibitor (DBI)-like neuropeptide is detected in human brain. Brain Res. 1986;399:136-142
Flipo M, Charton J, Hocine A, et al. Hydroxamates: Relationships between Structure and Plasma Stability. J Med Chem. 2009;52:6790-802
Fookes CJ, Pham TQ, Mattner F et al. Synthesis and Biological Evaluation of Substituted [18F]Imidazo-[1,2-a]pyridines and [18F]Pyrazolo[1,5-a]Pyrimidines for the study of the Peripheral Benzodiazepine Receptor Using Positron Emission Tomography.
J Med Chem. 2008;51:3700–12
Forsyth PA, Wong H, Laing TD, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer.
1999;79:1828-35
Fray AE, Ince PG, Banner SJ, et al. The expression of the glial glutamate transporter protein EAAT2 in motor neuron disease: an immunohistochemical study.
Eur J Neurosci. 1998;10:2481–89
Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96-107
Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–710
Gabelloni P, Da Pozzo E, Bendinelli S, et al. Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma.
Neuroscience. 2010;168:514-22
Gong YH, Parsadanian AS, Andreeva A et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. Journal of Neuroscience. 2000;20:660–5
vii
Gourine AV, Kasymov V, Marina N, et al. "Astrocytes control breathing through pH-dependent release of ATP". Science. 2010;329(5991):571–75
Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772–75
Halatsch ME, Schmidt U, Unterberg A, et al. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res. 2006;26:4191-4
Hald A and Lotharius J. Oxidative stress and inflammation in Parkinson’s Disease: is there a causal link? Exp Neurol. 2005;193:279–90
Hall ED, Oostveen EA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.
GLIA. 1998;23:249–56
Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res Rev. 2005;48:457-76
Hanessian S, MacKay DB, Moitessier N. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. J Med Chem. 2001;44:3074-82
Harraz MM, Marden JJ, Zhou W et al. SOD1mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. Journal of Clinical Investigation. 2008;118:659–70
He J, Reifenberger G, Liu L, et al. Analysis of glioma cell lines for amplification and overexpression of MDM2, Genes Chromosomes Cancer. 1994;11:91- 96
Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer. 1996;65:717-22
viii
Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res.
2001;61:1957-63
Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76-86
Jaarsma D, Teuling E, Haasdijk ED, et al. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. Journal of Neuroscience. 2008;28:2075–88
Jessen KR and Rhona M. Glial cells in the enteric nervous system contain glial fibrillary acidic protein. Nature. 1980;286:736-37
Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, et al. Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999.
Neuroepidemiology. 2004;23:101-9
Johansson CB, Momma S, Clarke DL, et al. Identification of a neural stem cell in the adult mammalian central nervous system. Cell. 1999;96:25–34
Joseph-Liauzun E, Delmas P, Shire D, et al. Topological analysis of the peripheral-type benzodiazepine receptor in yeast mitochondrial membrane. J Biol Chem. 1998;273:2146-52
Juven-Gershon T, Oren M. Mdm2: the ups and downs. Mol Med. 1999;5:71-83
Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101:2293-9
Kargiotis O, Chetty C, Gondi CS, et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced
ix
angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma, Oncogene. 2008;27:4830-40
Kawasaki Y, Xu ZZ, Wang X et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med. 2008;14:331–6
Kikuchi H, Almer G, Yamashita S et al. Spinal cord endoplasmic reticulum stress associated with a microsomal accumulation of mutant superoxide dismutase-1 in an ALS. Neurology Research International Model. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:6025–30
Kim SY, Lee EJ, Woo MS, et al. Inhibition of matrix metalloproteinase-9 gene expression by an isoflavone metabolite, irisolidone in U87MG human astroglioma cells.
Biochem Biophys Res Commun. 2008;366:493-9
Kiyama R, Tamura Y, Watanabe F, et al. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J Med Chem. 1998;42:1723-38
Kleihues P, Burger PC, Aldape KD, et al. World Health Organization Classification of Tumours of the Central Nervous System. 2007. IARC, Lyon
Kojima K, Konopleva M, Samudio IJ, et al. M. MDM2 antagonists induce p53- dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106:3150- 9
Komatsu K, Nakanishi Y, Nemoto N, et al. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas, Brain Tumor Pathol.
2004;21:105-12
Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, et al. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol.
2008;40:1156-68
x
Kotlo KU, Yehiely F, Efimova E, et al. Nrf2 is an inhibitor of the Fas pathway as identified by Achilles_ Heel Method, a new function-based approach to gene identification in human cells. Oncogene. 2003;22:797-806
Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2Yrelated factor 2Ydependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci. 2004;24:1101-12
Lacapère JJ, Papadopoulos V. Peripheral-type benzodiazepine receptor:
structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis. Steroids. 2003;68:569-85
Laks DR, Masterman-Smith M, Visnyei K, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells.
2009;27:980–7
Lee JM, Calkins MJ, Chan K, et al. Identification of the NF-E2-related factor- 2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem. 2003;278: 12029–38
Lee SK, Chun HK, Yang JY, et al. Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2. Bioorg Med Chem. 2007;15:4085–90
Lein M, Jung K, Le DK, et al. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. Prostate.
2000;43:77-82
Lepore AC, Rauck B, Dejea C, et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci.
2008;11:1294–1301
xi
Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system, in:
Jr V.T. De Vita, S. Hellman, S.A. Rosenberg (Eds.). Cancer principles of oncology.
Lippincott-Raven, Philadelphia. 2001:2100–61
Levin VA, Phuohanic S, Yung WKA, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78:295-302
Levitt NC, Eskens FA, O'Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res. 2001;7:1912-22
Liauw J, Hoang S, Choi M, et al. Thrombospondins 1 and 2 are necessary for synaptic plasticity and functional recovery after stroke. J. Cereb. Blood Flow Metab.
2008;28:1722–32
Lim SH, Jeong YI, Moon KS, et al. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide conjugated adriamycin against malignant glioma cells. Int J Pharm. 2009;387:209-14
Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. Journal of Neuroscience. 2002;22:4825–32
Liu J, Lillo C, Jonsson PA et al. Toxicity of familial ALSlinked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron. 2004;43:5–17
Liu-Chen LY, Li SX. Tallarida RJ. Studies on Kinetics of [3H]Beta- Funaltrexamine Binding to µ Opioid Receptor. Mol Pharmacol. 1990;37:243-50
Lobsiger CS and Cleveland DW. Glial cells as intrinsic component of non-cell- autonomous neurodegenerative disease. Nat. Neurosci. 2007;10:1355–60
xii
López-Otín C, Palavalli LH, Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle. 2009;8:3657-62
Lue L-F, Walker DG, Rogers J. Modeling microglial activation in Alzheimer’s disease with human post-mortem microglial cultures. Neurobiol Aging. 2002;22:945-56
Maaser K, Höpfner M, Jansen A, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001;85:1771-80
MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem. 1997;40:2525–32
Maes OC, Xu S, Yu B, et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007;28:1795–809
Maragakis NJ, Rothstein JD. Mechanisms of Disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006;2:679–89
Marchetto MCN, Muotri AR, Mu Y, et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649–57
Martini C, Lucacchini A. Affinity Labeling of Adenosine A1 Binding Sites. J.
Neurochem. 1987;49:681-4
Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem. 2001;277:5484-9
Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615–22
xiii
Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem.
1999;274:21491-4
Nakano I, Kornblum HI. Methods for analysis of brain tumor stem cell and neural stem cell self-renewal. Methods Mol Biol. 2009;568:37–56
Newman AH. Irreversible ligands as probes for drug receptors. NIDA Res Monogr. 1991;112:256-83. Review
Nuti E, Casalini F, Avramova SI, et al. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis. J Med Chem. 2009;52:4757-73
Nuti E, Panelli L, Casalini F, et al. Design, synthesis, biological evaluation and NMR studies of a new series of arylsulfones as selective and potent Matrix Metalloproteinase-12 inhibitors. J Med Chem. 2009;52:6347-61
Nuti E, Casalini F, Santamaria S et al. Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem. 2011;46:2617-29
Ohara PT, Vit JP, Bhargava A, et al. Evidence for a role of connexin 43 in trigeminal pain using RNA interference in vivo. J Neurophysiol. 2008;100:3064-73
Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci. 2009;100:2235-41
Orrell RW, Lane RJ, Ross M. Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database of Systematic Reviews. 2007;
Issue 1. Art. No.: CD002829. http://dx.doi.org/10.1002/14651858.CD002829.pub4
xiv
Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev.
Cancer. 2006;6:227-39
Papadopoulos V, Baraldi M, Guilarte TR et al. Translocator protein (18kDa):
new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402-9
Papadopoulos V, Boujrad N, Ikonomovic MD, et al. Topography of the Leydig cell mitochondrial peripheral-type benzodiazepine receptor. Mol Cell Endocrinol.
1994;104:R5–R9
Papadopoulos V, Dharmarajan AM, Li H, et al. Mitochondrial peripheral-type benzodiazepine receptor expression: correlation with the GnRH-agonist induced apoptosis in the corpus luteum. Biochem Pharmacol. 1999;58:1389-93
Papadopoulos V, Lecanu L. Translocator Protein (18 kDa) TSPO: An Emerging Therapeutic Target in Neurotrauma. Exp Neurol. 2009;219:53–7
Papi A, Bartolini G, Ammar K, et al. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line.
Oncol Rep. 2007;18:1015-21
Pasinelli P and Brown RH. Molecular biology of amyotrophic lateral sclerosis:
insights from genetics. Nature Reviews Neuroscience. 2006;7:710–23
Paterniti M. Driving Mr. Albert: A Trip across America with Einstein's Brain.
2001. Delta
Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res.
1990;50:6119-29
xv
Pehar M, Cassina P, Vargas MR, et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89:464–73
Perluigi M, Fai Poon H, Hensley K, et al. Proteomic analysis of 4-hydroxy-2- nonenal-modified proteins in G93A-SOD1 transgenic miceVa model of familial amyotrophic lateral sclerosis. Free Radic Biol Med. 2005;38:960-8
Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59:520-9
Pramatarova A, Lagani`ere J, Roussel J, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment.
Journal of Neuroscience. 2001;21:3369-74
Primofiore G, Da Settimo F, Taliani S, et al. N,N-Dialkyl-2-phenylindol-3- ylglyoxylamides. A New Class of Potent and Selective Ligands at the Peripheral Benzodiazepine Receptor. J Med Chem. 2004;47:1852-5
Puerta DT, Griffin MO, Lewis JA, et al. Heterocyclic zinc-binding groups for use in next-generation matrix metalloproteinase inhibitors: potency,toxicity, and reactivity. J Biol Inorg Chem. 2006;11:131-8
Puerta DT, Mongan J, Tran BL, et al. Potent, selective pyronebased inhibitors of stromelysin-1. J Am Chem Soc. 2005;127:14148-9
Rabbani SA, Harakidas P, Guo Y, et al. Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer. 2002;87:276-82
Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases.
Nat Rev. Cancer. 2003; 3:489-501
xvi
Rattray M, Bendotti C. Does excitotoxic cell death of motor neurons in ALS arise from glutamate transporter and glutamate receptor abnormalities? Exp Neurol.
2006;201:15–23
Roomi MW, Monterrey JC, Kalinovsky T, et al. Patterns of MMP-2 and MMP- 9 expression in human cancer cell lines. Oncol Rep. 2009;21:1323-33
Rosen DR, Siddique T, Patterson D et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature.
1993;362:59–62
Rossello A, Nuti E, Carelli P, et al. N-i-Propoxy-N- biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorg Med Chem Lett. 2005;15:1321-26
Rossello A, Nuti E, Orlandini E, et al. New N-arylsulfonyl- Nalkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
Bioorg Med Chem. 2004;12:2441-50
Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464–8
Rothstein JD, Patel S, Regan MR, et al. Betalactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–7
Rothstein JD, van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 amyotrophic lateral sclerosis. Annals of Neurology.
1995;38:73–84
Rozemuller AJ, van Gool WA, Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer’s disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord. 2005;4:223–33
xvii
Ruan S, Okcu MF, Pong RC, et al. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.
Clin Cancer Res. 1999;5:197-202
Salmaggi A, Boiardi A, Gelati M, et al. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 2006;54:850-60
Schoemaker H, Smith TL, Yamamura HI. Effect of chronic ethanol consumption on central and peripheral type benzodiazepine binding sites in the mouse brain. Brain Res. 1983;258:347-50
Schwab C, McGeer PL. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis. 2008;13:359–69
Secchiero P, Barbarotto E, Tiribelli M, et al. Functional integrity of the p53- mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2006;107:4122-9
Seifert G, Schilling K, Steinhauser C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci. 2006;7:194–206
Selleri S, Gratteri P, Costagli C, et al. Insight into 2-Phenylpyrazolo[1,5- a]pyrimidin-3-ylacetamides as Peripheral Benzodiazepine Receptor Ligands: Synthesis, Biological Evaluation and 3D-QSAR Investigation. Bioorg Med Chem. 2005;13:4821- 34
Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008;7:1533-42
xviii
Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem. 2005;280:22925-36
Silver J and Miller JH. Regeneration beyond the glial scar. Nat. Rev. Neurosci.
2004;5:146–56
Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401
Slobodyansky E, Guidotti A, Wambebe C, et al. Isolation and characterization of a rat brain triakontatetraneuropeptide, a posttranslational product of diazepam binding inhibitor: specific action at the Ro 5-4864 recognition site. J Neurochem.
1989;53:1276-84
Snyder MJ, Van Antwerpen R. Evidence for a diazepam-binding inhibitor (DBI) benzodiazepine receptor-like mechanism in ecdysteroidogenesis by the insect prothoracic gland. Cell Tissue Res. 1998;294:161-8
Sofroniew MV. Astrocyte failure as a cause of CNS dysfunction. Mol Psychiatry. 2000;5:230–2
Sorbera LA, Castaner J. Prinomastat: oncolytic, matrix metalloproteinase inhibitor. Drugs Fut. 2000;25:150-8
Stühmer T, Chatterjee M, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2003;106:3609-17
Syapin PJ, Skolnick P. Characterization of benzodiazepine binding sites in cultured cells of neural origin. J Neurochem. 1979;32:1047-51
Taliani S, Simorini F, Sergianni V, et al. New Fluorescent 2- Phenylindolglyoxylamide Derivatives as Probes Targeting the Peripheral-Type
xix
Benzodiazepine Receptor: Design, Synthesis, and Biological Evaluation. J Med Chem.
2007;50:404-7
Taliani S, Da Pozzo E, Bellandi M, et al. Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization. J Med Chem. 2010;27;53:4085-93
Tamura Y, Watanabe F, Nakatani T, et al. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem. 1998;41:640-9
Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix- metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 1999;80:764-72
Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103:1888-93
Turner BJ and Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Progress in Neurobiology.
2008;85:94–134
van Muiswinkel FL, Kuiperij HB. The Nrf2-ARE Signalling pathway:Promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord. 2005;4:267-81
Vargas MR, Johnson DA, Sirkis DW, et al. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. Journal of Neuroscience. 2008;28:13574–81
Vargas MR, Pehar M, Cassina P, et al. Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis. J Neurochem. 2006;97: 687–96
xx
Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-8
Ventura A, Kirsch DG, McLaughlin ME et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661-5
Verma A, Snyder SH. Peripheral type benzodiazepine receptors. Annu Rev Pharmacol Toxicol. 1989;29:307-22
Vihinen P, Kähäri VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157-66
Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, et al. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 2001;6:e18588
Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer.
2002;2:594-604
Wang L, Gutmann DH, Roos PR. Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. HumanMolecular Genetics.
2011;20:286–93
Wang L, Sharma K, Grisotti G, et al. The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis.
Neurobiology of Disease. 2009;35:234–40
Wang M, Wang T, Liu S et al. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol.
2003;20:65–72
Wang M, Yoshida D, Liu S, et al. Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study. J Neuro-Oncol. 2005;72:1-9
xxi
Wang X. Investigational anti-inflammatory agents for the treatment of ischaemic brain injury. Expert Opin Investig Drugs. 2005;14:393–409
Whittaker M, Floyd CD, Brown P, et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 1999;99:2735-76
Williamson TL and Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nature Neuroscience. 1999;2:50–6
Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer.
Cell Death Differ. 2006;13:921-6
Wolosker H, Dumin E, Balan L, et al. Amino acids in the brain: d-serine in neurotransmission and neurodegeneration. FEBS Journal. 2008;275(14):3514–26
Wu X, Bayle JH, Olson D et al. The p53-mdm-2 autoregulatory feedback loop.
Genes Dev. 1993 7:1126-32
Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445:656-60
Yamanaka K, Chun SJ, Boillee S et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nature Neuroscience.
2008;11:251–53
Yang Y, Gozen O, Watkins A et al. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron. 2009;61:880–94
Zhao P, Wang D, Gao Y, et al. Overexpression of MDM2, p53, and NCAM proteins in human radiation-induced skin ulcers. J Environ Pathol Toxicol Oncol.
1998;17:125-7
xxii
Zhong Z, Deane R, Ali Z et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nature Neuroscience. 2008;11:420–2
